Drug repurposing a reality: from computers to the clinic

Expert Review of Clinical Pharmacology

Volumn 6, Issue 2, 2013, Pages 95-97

  Issa, Naiem T ^a   Kruger, Jordan ^b   Byers, Stephen W ^a,b   Dakshanamurthy, Sivanesan ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cell network; chemoinformatics; docking; drug repurposing; drug target interactions; polypharmacology; screening; systems biology; systems pharmacology

Indexed keywords

AUTOMATION; COMPUTER MODEL; COST BENEFIT ANALYSIS; DATA PROCESSING; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDICATION; DRUG REPOSITIONING; HIGH THROUGHPUT SCREENING; LIGAND BINDING; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; REVIEW; SYSTEMS BIOLOGY; VIRTUAL REALITY;

COMPUTER SIMULATION; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY;

EID: 84874907312     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.79     Document Type: Review

References (19)

1. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010
2. Lawrence S. Pipelines turn to biotech. Nat. Biotechnol. 25(12), 1342 (2007
3. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J. Health Econ. 22(2), 151-185 (2003
4. Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3(8), 673-683 (2004
5. Lengauer T, Rarey M. Computational methods for biomolecular docking. Curr. Opin. Struct. Biol. 6(3), 402-406 (1996
6. Bohari MH, Sastry GN. FDA approved drugs complexed to their targets: Evaluating pose prediction accuracy of docking protocols. J. Mol. Model. 18(9), 4263-4274 (2012
7. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical systems biology: Repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput. Biol. 5(7), e1000423 (2009
8. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25(2), 197-206 (2007
9. Dakshanamurthy S, Issa NT, Assefnia S et al. Predicting new indications for approved drugs using a proteochemometric method. J. Med. Chem. 55(15), 6832-6848 (2012
10. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc. Natl Acad. Sci. USA 104(21), 8685-8690 (2007
11. Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug-target network. Nat. Biotechnol. 25(10), 1119-1126 (2007
12. Chiang AP, Butte AJ. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin. Pharmacol. Ther. 86(5), 507-510 (2009
13. Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS ONE 4(8), e6536 (2009
14. Huang H, Wu X, Pandey R et al. C2Maps: a network pharmacology database with comprehensive disease-gene-drug connectivity relationships. BMC Genomics 13, S17 (2012
15. Li C, Shang D, Wang Y et al. Characterizing the network of drugs and their affected metabolic subpathways. PLoS One 7(10), e47326 (2012
16. Mathur S, Dinakarpandian D. Drug repositioning using disease associated biological processes and network analysis of drug targets. AMIA Annu. Symp. Proc. 2011, 305-311 (2011
17. Sun J, Wu Y, Xu H, Zhao Z. DTome: A web-based tool for drug-target interactome construction. BMC Bioinformatics 13(Suppl. 9), S7 (2012)
18. Lamb J, Crawford ED, Peck D et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795), 1929-1935 (2006
19. Xie L, Evangelidis T, Xie L, Bourne PE. Drug discovery using chemical systems biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput. Biol. 7(4), e1002037 (2011